Key Publications about suPAR

suPAR Publications and links

Please always find our latest list of suPAR Publications and links to PubMed here:

suPAR Pub Med Publications and Links 2009-2020

The same PubMed list grouped by Organ and Disease here:

suPAR Pub Med Publications and Links – Organ and Disease grouped



Find the full list of suPAR abstracts in PubMed here

suPAR Monograph

On the basis of more than 600 published articles on suPAR in PubMed, a suPAR Monograph has been written.
Here you can find a short summary of the research done on suPAR within 12 groups of disease areas and see how the suPAR level is affected within each kind of disease.
The summary of each disease area is also found under Clinical Use.

Please find the suPAR Monograph here:

suPAR Monograph (English)
suPAR Monograph (Spanish)

Key suPAR publications

November, 2019

Soluble Urokinase Plasminogen Activator Receptor (suPAR) is predictive of Non-AIDS Events during Antiretroviral Therapy-mediated Viral Suppression” published in Clinical Infectious Diseases.

HIV infection remains associated with higher morbidity/mortality, partly driven by increased inflammation. The study by Martin Hoenigl et al. examines associations between levels of plasma biomarkers of chronic inflammation, microbial translocation, and monocyte activation, measured prior to and during suppressive ART, with occurrence of non-AIDS events.

Higher levels of suPAR were associated with increased risk of non-AIDS events. Higher levels of BDG and LBP at year one and pre-event were associated with increased risk of non-AIDS events. No associations were observed for other biomarkers.

The study concludes that elevated levels of suPAR were strongly, consistently and independently predictive of non-AIDS events at every measured time point. Interventions that target the suPAR pathway should be observed to explore its role in the pathogenesis of non-AIDS-related outcomes in HIV-infection.

Read the full article here

November, 2019

Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis” published in Journal of Clinical Laboratory Analysis.

This study aimed to explore the potential of suPAR as a biomarker for severe acute pancreatitis (SAP) risk prediction and disease management in SAP patients. It was conducted at the First Affiliated Hospital of Harbin Medical University in China with 225 acute pancreatitis (AP) patients. The suPAR level was increased in SAP patients compared with MSAP patients, MAP patients and HCs.

The authors conclude that suPAR is of good predictive value for SAP risk and may serve as a potential biomarker for disease severity, inflammation, and in hospital mortality in SAP patients.

Read the full open access article here

November, 2019

The biomarkers suPAR and blood eosinophils are associated with hospital readmissions and mortality in asthma – a retrospective cohort study” published in Respiratory Research.

The biomarker suPAR has been associated with asthma control and with prognosis in acutely admitted medical patients. This study by KEJ Håkansson and coworkers investigates if suPAR and blood eosinophil counts at the time of admission for asthma are associated with readmission and mortality.

The study included 1341 patients who were acutely admitted to Hvidovre Hospital in Denmark with an asthma diagnosis. In comparison to event-free patients, patients that were readmitted or that died had significantly higher suPAR concentrations (p<0.0001) and lower eosinophil counts (p = 0.0031) at admission.

The authors conclude that elevated suPAR levels, together with the eosinophil count, were associated with 365-day readmission and mortality in patients acutely admitted with asthma.

Read the full open access article here

November, 2019

Association of Adverse Experiences and Exposure to Violence in Childhood and Adolescence With Inflammatory Burden in Young People” published in Jamapedriatrics.

Line JH Rasmussen and coworkers investigated whether exposure to stress and violence in childhood leads to elevated suPAR levels in adulthood.

1391 participants from a 1994 to 1995 birth cohort of twins were followed up until they reached 18 years of age. Individuals exposed to multiple types of violence in both childhood and adolescence had higher suPAR levels compared with children who did not experience stress or violence. They were significantly more likely to have elevated suPAR levels even if they did not have elevated CRP or IL-6 levels.

The results suggest that adult inflammation is highly associated with childhood exposure to stress. Adding suPAR to traditional biomarkers may improve measurement of stress-related inflammatory burden.

Find the publication here

August, 2019

High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma” published in Carcinogenesis.

Many pancreatic adenocarcinoma (PDAC) patients are still facing an unfavorable prognosis after complete tumor resection, meaning that better preoperative stratification algorithms are needed. The study by Sven H Loosen and coworkers explored the role of suPAR for patients undergoing resection.

PDAC patients had a significantly elevated suPAR level compared to the healthy control group and patients with PDAC precursor lesions. Patients with a high preoperative suPAR level also showed a significantly reduced overall survival after resection. The prognostic role of suPAR was further reinforced by Cox-regression analyses and high suPAR levels also identified patients particularly susceptible to acute kidney injury and surgical complications after surgery.

The study concludes that suPAR might be a useful addition to existing preoperative stratification algorithms for identifying patients that benefit from extended tumor resection.

Read the full article here

June, 2019

Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes” published in Diabetes Care.

Despite being an important inflammatory biomarker implicated in endothelial and podocyte dysfunction, suPAR’s predictive qualities for complications in type 1 diabetes have yet to be determined. This study by Viktor Rotbain Curovic et al., including 667 participants, investigated the value of suPAR for the prognostic value for the development of cardiovascular events, decline in renal function, and mortality in patients with type 1 diabetes.

A higher level of suPAR showed to be a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality. suPAR also significantly contributes to discrimination for the end points.

Read the full article here

May, 2019

Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy” published in Disease Markers.

The authors of this study investigated whether the prognostic biomarker suPAR can help in the early identification of patients at low risk of serious illness. 16.801 acutely admitted patients at two university hospitals in the Capital Region of Denmark were compared related to whether they had a valid supAR measurement at admission or not.

The proportion of patients who were discharged within 24 hours of admittance was significantly higher in the suPAR group compared to the control group (50.2% vs. 48.6%), while mean length of hospital stay in the suPAR group was shorter compared to the control group (4.3 days vs. 4.6 days). In contrast, the readmission rate within 30 days was higher in the suPAR group (10.6% vs. 8.8%). Among patients discharged within 24 hours, there was no significant difference in the readmission rate or mortality within 30 days.

The study demonstrates that the availability of suPAR was associated with a higher proportion of discharge within 24 hours and reduced length of stay, but more readmissions. In patients discharged within 24 hours, there was no difference in readmission or mortality.

Read the full open access article here

April, 2019

Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial” published in Scandinavian journal of trauma, resuscitation and emergency medicine.

The blood level of suPAR might be usable for the identification of ED patients at high-and low risk. This study by Martin Schultz and coworkers investigates the value of adding suPAR to triage and how this could impact risk stratification regarding mortality.

suPAR was significantly better in predicting mortality than triage. Combining suPAR and triage yielded an AUC of 0.87. The Youden’s index cut-off value of suPAR was 5.9 ng/ml and reclassified triage using this value resulted in a more accurate risk stratification regarding hospital admission and mortality.

The study concluded that adding suPAR to triage potentially improves short-term mortality prediction. Measurement of suPAR in relation to the triage process may allow a more accurate identification of ED patients at risk.

Read the full open access article here

March, 2019

“Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality” published in British Journal of Nutrition.

suPAR is a stable marker of chronic inflammation, which is associated with disease risk and mortality. Higher levels of suPAR are found in individuals with an unhealthy lifestyle.

This study with 5347 participants by Peter BS Törnkvist and coworkers investigates the relation between suPAR and dietary quality measured with the dietary quality score (DQS). It also examines the association of both suPAR and the DQS with CVD risk and mortality in the general Danish population.

Multiple linear regression analyses showed a linear reverse association between the DQS